Johnson & Johnson (NYSE:JNJ) Stock Bought Rep. Bruce Westerman

Representative Bruce Westerman (R-Arkansas) recently bought shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on April 16th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on March 3rd.

Representative Bruce Westerman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of LVMH Moët Hennessy - Louis Vuitton, Société Européenne OTCMKTS: LVMUY on 4/2/2025.
• Purchased $1,001 - $15,000 in shares of Sony Group NYSE: SONY on 3/24/2025.
• Purchased $1,001 - $15,000 in shares of Mitsubishi UFJ Financial Group NYSE: MUFG on 3/21/2025.
• Purchased $1,001 - $15,000 in shares of BP NYSE: BP on 3/21/2025.
• Sold $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 3/20/2025.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $1.02 during midday trading on Tuesday, reaching $157.94. 1,201,420 shares of the company were exchanged, compared to its average volume of 7,913,111. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a fifty day simple moving average of $159.53 and a 200 day simple moving average of $154.93. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $380.60 billion, a P/E ratio of 23.76, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.29%. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on JNJ shares. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research report on Thursday, January 23rd. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. IFS Advisors LLC increased its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $32,000. Finally, Conquis Financial LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

About Representative Westerman

Bruce Westerman (Republican Party) is a member of the U.S. House, representing Arkansas' 4th Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027. Westerman (Republican Party) is running for re-election to the U.S. House to represent Arkansas' 4th Congressional District. He declared candidacy for the 2026 election. Westerman earned his BSBAGE in biological and agricultural engineering from the University of Arkansas in 1990 and his MF in forestry from Yale University in 2001. His professional experience includes working as a plant engineer for Riceland Foods and an engineer/forester for Mid-South Engineering Company.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.